Regenxbio reports 5-year wet AMD efficacy data for sura-vec gene therapy at ASRS meeting

REGENXBIO, Inc.

REGENXBIO, Inc.

RGNX

0.00
  • Regenxbio reported positive long-term follow-up data for surabgene lomparvovec in wet AMD and diabetic retinopathy, supporting durability from a one-time treatment.
  • Wet AMD Phase I/IIa cohorts showed stable to improved vision through 5 years, with reduced anti-VEGF injection burden, at doses used in pivotal studies.
  • Diabetic retinopathy ALTITUDE follow-up showed 55% achieved >2-step DRSS improvement at 2.5 years, with 70% avoiding vision-threatening events.
  • Topline results from the ATMOSPHERE and ASCENT pivotal wet AMD trials are expected in Q4 2026, a key catalyst for the program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607181455PR_NEWS_USPR_____PH07513) on July 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.